{"gene":"TNFRSF10C","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1997,"finding":"TRAIL-R3 (TNFRSF10C) is a plasma membrane-bound protein that binds TRAIL with high affinity but lacks a cytoplasmic domain and is instead glycosyl-phosphatidylinositol (GPI)-linked; unlike TRAIL-R1 and TRAIL-R2, overexpression of TRAIL-R3 does not induce apoptosis in a transient expression system.","method":"Cloning, transient expression, quantitative TRAIL binding studies, structural analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 — original cloning paper with direct binding assays, structural characterization, and functional overexpression studies; foundational study replicated across multiple subsequent works","pmids":["9314565"],"is_preprint":false},{"year":1999,"finding":"TRAIL-R3 (TRID) functions as an antiapoptotic decoy receptor that competes with DR4 and DR5 for TRAIL binding, thereby protecting cells from TRAIL-induced apoptosis; TRID gene expression is induced by genotoxic agents (ionizing radiation, MMS) in a p53-dependent manner, identifying TRID as a p53-regulated DNA damage-inducible gene.","method":"Reporter assays, genotoxic agent treatment, exogenous p53 expression in p53-null cells, RT-PCR","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (p53 overexpression, genotoxic stress, RT-PCR) in a single study; replicated by subsequent independent labs","pmids":["10435597"],"is_preprint":false},{"year":2001,"finding":"Rel/NF-κB transcription factors upregulate DcR1 (TNFRSF10C) expression, and this upregulation confers TRAIL resistance; the resistance is abolished when DcR1 is removed from the cell surface by phosphatidylinositol phospholipase C treatment, establishing the GPI-anchored DcR1 as a dominant-negative inhibitor of TRAIL-mediated apoptosis at the membrane level.","method":"DNA arrays, RT-PCR, immunofluorescence, overexpression of cRel, TNFα stimulation, phosphatidylinositol-PLC treatment to remove cell-surface DcR1, TRAIL apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches including gain-of-function, pharmacological removal of surface receptor, and functional apoptosis rescue; single lab but strong mechanistic rigor","pmids":["11350953"],"is_preprint":false},{"year":2002,"finding":"Tumor-specific loss of DcR1 (TNFRSF10C) expression in neuroblastoma and other tumor cell lines is caused by dense CpG island hypermethylation of the DcR1 promoter; treatment with the demethylating agent 5-aza-2'-deoxycytidine partially restores DcR1 mRNA expression.","method":"Bisulfite sequencing, methylation analysis, 5-aza-2'-deoxycytidine demethylation treatment, RT-PCR","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — demethylation rescue experiment directly links promoter methylation to silencing; independently replicated across multiple tumor types in multiple subsequent studies","pmids":["11929838"],"is_preprint":false},{"year":2003,"finding":"The TRAIL-R3 (TNFRSF10C) gene contains a p53 consensus binding element within its first intron; this element binds p53 and confers responsiveness to genotoxic damage in luciferase reporter assays, establishing a direct transcriptional regulatory mechanism by which p53 induces TRAIL-R3 expression.","method":"Promoter cloning, transient transfection luciferase reporter assays, electrophoretic mobility shift assay (p53 binding to intronic element), p53 mutant and E6-expressing cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct p53 binding to a defined intronic element demonstrated with multiple genetic controls (temperature-sensitive p53, E6-mediated p53 degradation, p53-null cells); mechanistic rigor is strong","pmids":["14623878"],"is_preprint":false},{"year":2003,"finding":"The minimal promoter of TRAIL-R3 lies within 33 nucleotides upstream of the transcription start site and contains a consensus TATA box; the promoter can be induced in doxorubicin-treated MCF-7 cells also in a p53-independent manner.","method":"Promoter cloning, mapping of transcriptional start sites, transient transfection luciferase reporter assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay directly demonstrates promoter activity; single lab with limited mechanistic follow-up on p53-independent induction","pmids":["12417331"],"is_preprint":false},{"year":2008,"finding":"In p53 wild-type colon cancer cells, oxaliplatin causes p53-dependent upregulation of DcR1, which then sequesters TRAIL and blunts TRAIL-induced apoptosis; siRNA knockdown of DcR1 restores oxaliplatin/TRAIL synergistic apoptosis, and exogenous DcR1 overexpression in p53-mutant cells abolishes this synergy, demonstrating that DcR1 acts downstream of p53 to inhibit TRAIL signaling.","method":"siRNA knockdown of DcR1, exogenous DcR1 overexpression, apoptosis assays across multiple colon cancer cell lines with defined p53 status","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain- and loss-of-function experiments with defined p53 genetic background; multiple cell lines tested","pmids":["18345033"],"is_preprint":false},{"year":2009,"finding":"TNFRSF10C is inactivated in prostate cancer through a combination of hemizygous chromosomal deletion and promoter CpG island hypermethylation; demethylation of the promoter with 5-aza-2'-deoxycytidine in PC3 cells restores TNFRSF10C mRNA expression, demonstrating that promoter methylation is a mechanistic cause of gene silencing.","method":"Bisulfite sequencing, Affymetrix SNP array for deletion analysis, 5-aza-2'-deoxycytidine treatment, real-time RT-PCR in clinical specimens and cell lines","journal":"The Prostate","confidence":"High","confidence_rationale":"Tier 2 — demethylation rescue in cell line plus genomic deletion mapping in clinical specimens; two independent silencing mechanisms characterized","pmids":["19035483"],"is_preprint":false},{"year":2011,"finding":"Down-modulation of TRAIL-R3 in AML blasts enhances TRAIL-induced cell death, confirming its functional role as a decoy receptor on leukemic cells; high TRAIL-R3 expression confers resistance to soluble TRAIL-induced apoptosis.","method":"Flow cytometry, siRNA-mediated knockdown of TRAIL-R3, TRAIL apoptosis assays in primary AML blasts","journal":"Leukemia research","confidence":"Medium","confidence_rationale":"Tier 2 — functional knockdown with defined apoptosis readout in primary patient material; single lab","pmids":["21269942"],"is_preprint":false},{"year":2015,"finding":"DcR1 (TNFRSF10C) is induced by temozolomide in glioma cells through a p50/NF-κB1- and Bcl3-dependent mechanism requiring a conserved κB-site in the proximal DcR1 promoter; DcR1 attenuates temozolomide efficacy by blunting Fas receptor pathway activation, and DcR1 depletion enhances temozolomide efficacy in intracranial xenografts.","method":"NF-κB reporter assays, κB-site mutagenesis, loss-of-function (siRNA) and gain-of-function DcR1 studies, intracranial xenograft model, apoptosis assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — promoter mutagenesis, reciprocal loss/gain of function, in vivo xenograft validation; multiple orthogonal methods in single study","pmids":["25808868"],"is_preprint":false},{"year":2020,"finding":"HIF-1α negatively regulates DcR1 expression following traumatic brain injury; pharmacological inhibition of HIF-1α or HIF-1α siRNA increases DcR1 expression in neurons, which in turn reduces TRAIL/DR5-mediated neuronal apoptosis, placing DcR1 downstream of HIF-1α in the TRAIL apoptotic pathway.","method":"HIF-1α inhibitor (2ME) and agonist (DMOG) treatment in rat TBI model, HIF-1α siRNA in vitro, Western blot, immunofluorescence, TRAIL/DR5 blockade with soluble DR5","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo pharmacological and in vitro siRNA approaches converge; single lab with multiple methods","pmids":["32848609"],"is_preprint":false},{"year":2023,"finding":"Hepatitis B virus (HBV) upregulates TRAIL-R3 expression in hepatocytes through hepatitis B x (HBx) protein-mediated activation of NF-κB signaling acting on the TRAIL-R3 promoter region (-969 to -479 upstream of transcription start); TRAIL-R3 upregulation inhibits both TRAIL-dependent apoptosis and TRAIL-mediated suppression of HBV replication, providing a mechanism for HBV immune escape.","method":"cDNA microarray and NGS in HBV-infected humanized mouse livers, in vitro HBV replication models, luciferase promoter assays, antiviral nucleotide treatment, in vivo and in vitro validation","journal":"The Journal of infectious diseases","confidence":"High","confidence_rationale":"Tier 1-2 — promoter mapping, in vivo and in vitro HBV replication models, antiviral rescue; multiple orthogonal methods with mechanistic resolution","pmids":["35226068"],"is_preprint":false}],"current_model":"TNFRSF10C (DcR1/TRAIL-R3) is a GPI-anchored, cytoplasmic domain-lacking decoy receptor that binds TRAIL with high affinity but fails to transduce apoptotic signals, instead acting as a dominant-negative inhibitor of TRAIL-mediated apoptosis by competing with death receptors DR4 and DR5; its expression is transcriptionally upregulated by p53 (via an intronic p53-binding element) and NF-κB (via a proximal κB-site, requiring Bcl3/p50), and is epigenetically silenced in many tumors through CpG island promoter hypermethylation, while HBV exploits NF-κB/HBx-mediated TRAIL-R3 induction to escape immune surveillance."},"narrative":{"teleology":[{"year":1997,"claim":"Identification of TRAIL-R3 as a GPI-anchored receptor that binds TRAIL but cannot signal apoptosis resolved how cells could engage TRAIL without dying, establishing the decoy receptor concept for TRAIL biology.","evidence":"Cloning, quantitative TRAIL-binding assays, structural analysis, and transient overexpression in cell lines","pmids":["9314565"],"confidence":"High","gaps":["No endogenous loss-of-function data to confirm physiological decoy role","Mechanism by which GPI anchor prevents signaling not elucidated"]},{"year":1999,"claim":"Demonstrating that DcR1 is a p53-inducible DNA damage-response gene explained how genotoxic stress could paradoxically protect certain cells from TRAIL-mediated killing.","evidence":"RT-PCR and reporter assays after ionizing radiation and MMS in cells with or without functional p53","pmids":["10435597"],"confidence":"High","gaps":["Direct p53 binding site not yet mapped","Physiological relevance of p53-mediated DcR1 induction in vivo not tested"]},{"year":2001,"claim":"Showing that NF-κB upregulates surface DcR1 and that its enzymatic removal restores TRAIL sensitivity established DcR1 as a dominant-negative TRAIL inhibitor operating at the plasma membrane.","evidence":"cRel overexpression, TNFα stimulation, PI-PLC cleavage of GPI-anchored DcR1, and TRAIL apoptosis assays","pmids":["11350953"],"confidence":"High","gaps":["Specific NF-κB binding site in DcR1 promoter not mapped","Contribution of individual NF-κB subunits not determined"]},{"year":2002,"claim":"Discovery that DcR1 promoter CpG island hypermethylation causes tumor-specific silencing revealed an epigenetic mechanism by which cancers lose a TRAIL decoy, with implications for TRAIL-based therapy sensitivity.","evidence":"Bisulfite sequencing in neuroblastoma and other tumor lines; 5-aza-2′-deoxycytidine restores expression","pmids":["11929838"],"confidence":"High","gaps":["Whether methylation-mediated DcR1 loss sensitizes tumors to endogenous TRAIL in vivo not shown","Mechanism recruiting methyltransferases to DcR1 locus unknown"]},{"year":2003,"claim":"Mapping of a p53-binding element in the first intron and delineation of the minimal TATA-box-containing promoter provided the direct cis-regulatory architecture for p53-dependent and p53-independent transcriptional control of DcR1.","evidence":"EMSA demonstrating p53 binding to intronic element; luciferase reporter assays with wild-type and mutant p53, E6-expressing cells, and promoter deletions","pmids":["14623878","12417331"],"confidence":"High","gaps":["Chromatin context of p53 binding (ChIP) not shown","Identity of p53-independent transcriptional activators in doxorubicin-treated cells unknown"]},{"year":2008,"claim":"Reciprocal knockdown and overexpression of DcR1 across p53-defined colon cancer lines demonstrated that p53-driven DcR1 induction functionally antagonizes oxaliplatin/TRAIL synergy, establishing DcR1 as a druggable resistance node in combination therapy.","evidence":"siRNA knockdown and forced expression of DcR1 in colon cancer lines with defined p53 status; apoptosis quantification","pmids":["18345033"],"confidence":"High","gaps":["Whether DcR1 depletion improves combination therapy in vivo not tested","Stoichiometric relationship between DcR1 and DR4/DR5 on surface not quantified"]},{"year":2009,"claim":"Identification of concurrent hemizygous deletion and promoter methylation in prostate cancer showed that biallelic inactivation of DcR1 occurs through complementary genetic and epigenetic hits.","evidence":"SNP array for copy-number analysis and bisulfite sequencing in clinical prostate cancer specimens; 5-aza-2′-deoxycytidine rescue in PC3 cells","pmids":["19035483"],"confidence":"High","gaps":["Functional consequence of DcR1 loss for prostate cancer TRAIL sensitivity not tested directly","Whether deletion is selected for or bystander to neighboring loci unclear"]},{"year":2015,"claim":"Defining the proximal κB-site and p50/Bcl3 dependence for temozolomide-induced DcR1 expression, together with in vivo xenograft validation, resolved the specific NF-κB subunit pathway and established DcR1 depletion as a strategy to enhance alkylating-agent therapy in glioma.","evidence":"κB-site mutagenesis in reporter, siRNA/overexpression of DcR1, intracranial xenograft survival studies","pmids":["25808868"],"confidence":"High","gaps":["ChIP confirmation of endogenous p50/Bcl3 occupancy at κB-site not provided","Whether DcR1 inhibits Fas pathway by direct ligand competition or indirect mechanism not resolved"]},{"year":2020,"claim":"Placing DcR1 downstream of HIF-1α as a negatively regulated target in traumatic brain injury added a hypoxia-responsive layer to DcR1 transcriptional control in neurons.","evidence":"HIF-1α inhibitor/agonist treatment in rat TBI model and HIF-1α siRNA in vitro; Western blot and immunofluorescence","pmids":["32848609"],"confidence":"Medium","gaps":["Direct HIF-1α binding to DcR1 promoter not demonstrated","Mechanism of negative regulation (direct repression vs. indirect) unknown","Single-lab finding not yet independently replicated"]},{"year":2023,"claim":"Demonstrating that HBV/HBx upregulates DcR1 via NF-κB to simultaneously block TRAIL-mediated apoptosis and TRAIL-dependent antiviral suppression revealed a viral immune evasion strategy centered on the decoy receptor.","evidence":"cDNA microarray/NGS in HBV-infected humanized mouse livers, luciferase promoter assays mapping -969 to -479 region, in vitro HBV replication models, antiviral rescue","pmids":["35226068"],"confidence":"High","gaps":["Exact NF-κB binding element within the -969 to -479 region not fine-mapped","Whether other hepatotropic viruses exploit DcR1 similarly is untested"]},{"year":null,"claim":"The structural basis for TRAIL binding by GPI-anchored DcR1, the precise stoichiometry of DcR1/DR4/DR5 competition at the membrane, and whether DcR1 has signaling-independent functions beyond ligand sequestration remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of DcR1–TRAIL complex","Quantitative surface competition model with DR4/DR5 lacking","Potential non-apoptotic signaling through lipid-raft-associated DcR1 unexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2,6,8]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,2,6,8,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,4,9,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11]}],"complexes":[],"partners":["TNFSF10","TP53","NFKB1","BCL3","HBX"],"other_free_text":[]},"mechanistic_narrative":"TNFRSF10C (DcR1/TRAIL-R3) is a GPI-anchored decoy receptor that binds TRAIL with high affinity but lacks a cytoplasmic death domain, thereby competing with the death receptors DR4 and DR5 to inhibit TRAIL-mediated apoptosis at the cell surface [PMID:9314565, PMID:11350953]. Its expression is transcriptionally controlled by p53, which binds a consensus element in the first intron to upregulate DcR1 after genotoxic stress, and by NF-κB, which acts through a proximal κB-site in a p50/Bcl3-dependent manner [PMID:14623878, PMID:25808868]. In many cancers DcR1 is epigenetically silenced by CpG island promoter hypermethylation, sometimes in combination with hemizygous deletion, and demethylation restores its expression [PMID:11929838, PMID:19035483]. Hepatitis B virus exploits HBx-mediated NF-κB activation of the DcR1 promoter to upregulate DcR1 in hepatocytes, thereby blunting TRAIL-dependent immune clearance and antiviral suppression of HBV replication [PMID:35226068]."},"prefetch_data":{"uniprot":{"accession":"O14798","full_name":"Tumor necrosis factor receptor superfamily member 10C","aliases":["Antagonist decoy receptor for TRAIL/Apo-2L","Decoy TRAIL receptor without death domain","Decoy receptor 1","DcR1","Lymphocyte inhibitor of TRAIL","TNF-related apoptosis-inducing ligand receptor 3","TRAIL receptor 3","TRAIL-R3","TRAIL receptor without an intracellular domain"],"length_aa":259,"mass_kda":27.4,"function":"Receptor for the cytotoxic ligand TRAIL. Lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. May protect cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O14798/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF10C","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF10C","total_profiled":1310},"omim":[{"mim_id":"610562","title":"ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 12A; ZC3H12A","url":"https://www.omim.org/entry/610562"},{"mim_id":"603613","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 10C; TNFRSF10C","url":"https://www.omim.org/entry/603613"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":19.8},{"tissue":"lymphoid tissue","ntpm":22.4}],"url":"https://www.proteinatlas.org/search/TNFRSF10C"},"hgnc":{"alias_symbol":["DcR1","TRAILR3","LIT","TRID","CD263"],"prev_symbol":[]},"alphafold":{"accession":"O14798","domains":[{"cath_id":"2.10.50.10","chopping":"53-112","consensus_level":"medium","plddt":96.7797,"start":53,"end":112},{"cath_id":"2.10.50","chopping":"114-153","consensus_level":"medium","plddt":94.143,"start":114,"end":153}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14798","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14798-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14798-F1-predicted_aligned_error_v6.png","plddt_mean":71.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF10C","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF10C"},"sequence":{"accession":"O14798","fasta_url":"https://rest.uniprot.org/uniprotkb/O14798.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14798/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14798"}},"corpus_meta":[{"pmid":"11486053","id":"PMC_11486053","title":"A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans.","date":"2001","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11486053","citation_count":683,"is_preprint":false},{"pmid":"9314565","id":"PMC_9314565","title":"Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9314565","citation_count":529,"is_preprint":false},{"pmid":"12110183","id":"PMC_12110183","title":"The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DExH-box helicase to direct RNAi in C. elegans.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12110183","citation_count":373,"is_preprint":false},{"pmid":"16439208","id":"PMC_16439208","title":"Functional proteomics reveals the biochemical niche of C. elegans DCR-1 in multiple small-RNA-mediated pathways.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16439208","citation_count":310,"is_preprint":false},{"pmid":"10380924","id":"PMC_10380924","title":"WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in C. elegans.","date":"1999","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10380924","citation_count":225,"is_preprint":false},{"pmid":"32282202","id":"PMC_32282202","title":"LIT-PCBA: An Unbiased Data Set for Machine Learning and Virtual Screening.","date":"2020","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/32282202","citation_count":153,"is_preprint":false},{"pmid":"18760458","id":"PMC_18760458","title":"Myosin light chain is a novel shrimp allergen, Lit v 3.","date":"2008","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18760458","citation_count":145,"is_preprint":false},{"pmid":"11929838","id":"PMC_11929838","title":"Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11929838","citation_count":135,"is_preprint":false},{"pmid":"8603394","id":"PMC_8603394","title":"Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8603394","citation_count":133,"is_preprint":false},{"pmid":"17306537","id":"PMC_17306537","title":"Dcr-1 maintains Drosophila ovarian stem cells.","date":"2007","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/17306537","citation_count":131,"is_preprint":false},{"pmid":"10435597","id":"PMC_10435597","title":"The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10435597","citation_count":122,"is_preprint":false},{"pmid":"10488343","id":"PMC_10488343","title":"MOM-4, a MAP kinase kinase kinase-related protein, activates WRM-1/LIT-1 kinase to transduce anterior/posterior polarity signals in C. elegans.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10488343","citation_count":100,"is_preprint":false},{"pmid":"11350953","id":"PMC_11350953","title":"Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11350953","citation_count":98,"is_preprint":false},{"pmid":"2481813","id":"PMC_2481813","title":"Cloning and characterization of mouse growth hormone-releasing hormone (GRH) complementary DNA: increased GRH messenger RNA levels in the growth hormone-deficient lit/lit mouse.","date":"1989","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2481813","citation_count":97,"is_preprint":false},{"pmid":"23470582","id":"PMC_23470582","title":"Gut-associated biomarkers L-FABP, I-FABP, and TFF3 and LIT score for diagnosis of surgical necrotizing enterocolitis in preterm infants.","date":"2013","source":"Annals of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/23470582","citation_count":70,"is_preprint":false},{"pmid":"35556139","id":"PMC_35556139","title":"Towards Large-Scale Integrative Taxonomy (LIT): Resolving the Data Conundrum for Dark Taxa.","date":"2022","source":"Systematic biology","url":"https://pubmed.ncbi.nlm.nih.gov/35556139","citation_count":68,"is_preprint":false},{"pmid":"15788647","id":"PMC_15788647","title":"Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas.","date":"2005","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15788647","citation_count":55,"is_preprint":false},{"pmid":"22179787","id":"PMC_22179787","title":"Tudor domain ERI-5 tethers an RNA-dependent RNA polymerase to DCR-1 to potentiate endo-RNAi.","date":"2011","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22179787","citation_count":52,"is_preprint":false},{"pmid":"9299242","id":"PMC_9299242","title":"A new inward rectifier potassium channel gene (KCNJ15) localized on chromosome 21 in the Down syndrome chromosome region 1 (DCR1).","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9299242","citation_count":47,"is_preprint":false},{"pmid":"21857800","id":"PMC_21857800","title":"Opposing activities of LIT-1/NLK and DAF-6/patched-related direct sensory compartment morphogenesis in C. elegans.","date":"2011","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/21857800","citation_count":46,"is_preprint":false},{"pmid":"7595148","id":"PMC_7595148","title":"GH-deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6.","date":"1995","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7595148","citation_count":45,"is_preprint":false},{"pmid":"30199637","id":"PMC_30199637","title":"LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30199637","citation_count":39,"is_preprint":false},{"pmid":"14699070","id":"PMC_14699070","title":"ago1 and dcr1, two core components of the RNA interference pathway, functionally diverge from rdp1 in regulating cell cycle events in Schizosaccharomyces pombe.","date":"2003","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/14699070","citation_count":39,"is_preprint":false},{"pmid":"18345033","id":"PMC_18345033","title":"P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18345033","citation_count":38,"is_preprint":false},{"pmid":"14623878","id":"PMC_14623878","title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14623878","citation_count":38,"is_preprint":false},{"pmid":"15308683","id":"PMC_15308683","title":"Muscle mechano growth factor is preferentially induced by growth hormone in growth hormone-deficient lit/lit mice.","date":"2004","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15308683","citation_count":32,"is_preprint":false},{"pmid":"2414679","id":"PMC_2414679","title":"Microcephalic cerebrum with hypomyelination in the growth hormone-deficient mouse (lit).","date":"1985","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/2414679","citation_count":31,"is_preprint":false},{"pmid":"21281967","id":"PMC_21281967","title":"High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.","date":"2011","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/21281967","citation_count":31,"is_preprint":false},{"pmid":"19035483","id":"PMC_19035483","title":"Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.","date":"2009","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/19035483","citation_count":28,"is_preprint":false},{"pmid":"12355407","id":"PMC_12355407","title":"Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation.","date":"2002","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12355407","citation_count":27,"is_preprint":false},{"pmid":"29145848","id":"PMC_29145848","title":"Pharmacological potential of Bidens pilosa L. and determination of bioactive compounds using UHPLC-QqQLIT-MS/MS and GC/MS.","date":"2017","source":"BMC complementary and alternative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29145848","citation_count":25,"is_preprint":false},{"pmid":"27392085","id":"PMC_27392085","title":"Speciation and ecological success in dimly lit waters: horizontal gene transfer in a green sulfur bacteria bloom unveiled by metagenomic assembly.","date":"2016","source":"The ISME journal","url":"https://pubmed.ncbi.nlm.nih.gov/27392085","citation_count":25,"is_preprint":false},{"pmid":"15520513","id":"PMC_15520513","title":"Functional analysis of genes implicated in Down syndrome: 1. Cognitive abilities in mice transpolygenic for Down Syndrome Chromosomal Region-1 (DCR-1).","date":"2004","source":"Behavior genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15520513","citation_count":25,"is_preprint":false},{"pmid":"37290322","id":"PMC_37290322","title":"The effect of lymphocyte immunotherapy (LIT) in modulating immune responses in patients with recurrent pregnancy loss (RPL).","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37290322","citation_count":24,"is_preprint":false},{"pmid":"28850112","id":"PMC_28850112","title":"Decreased AGO2 and DCR1 in PBMCs from War Veterans with PTSD leads to diminished miRNA resulting in elevated inflammation.","date":"2017","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/28850112","citation_count":23,"is_preprint":false},{"pmid":"34170668","id":"PMC_34170668","title":"Identification of the Dominant T-Cell Epitopes of Lit v 1 Shrimp Major Allergen and Their Functional Overlap with Known B-Cell Epitopes.","date":"2021","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34170668","citation_count":23,"is_preprint":false},{"pmid":"24061001","id":"PMC_24061001","title":"Mono-dimensional blue native-PAGE and bi-dimensional blue native/urea-PAGE or/SDS-PAGE combined with nLC-ESI-LIT-MS/MS unveil membrane protein heteromeric and homomeric complexes in Streptococcus thermophilus.","date":"2013","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/24061001","citation_count":22,"is_preprint":false},{"pmid":"33488071","id":"PMC_33488071","title":"Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.","date":"2021","source":"International journal of chronic obstructive pulmonary disease","url":"https://pubmed.ncbi.nlm.nih.gov/33488071","citation_count":21,"is_preprint":false},{"pmid":"29859917","id":"PMC_29859917","title":"Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.","date":"2018","source":"Contemporary clinical trials","url":"https://pubmed.ncbi.nlm.nih.gov/29859917","citation_count":21,"is_preprint":false},{"pmid":"20878948","id":"PMC_20878948","title":"Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression.","date":"2010","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/20878948","citation_count":20,"is_preprint":false},{"pmid":"15219942","id":"PMC_15219942","title":"Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15219942","citation_count":19,"is_preprint":false},{"pmid":"21269942","id":"PMC_21269942","title":"Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines.","date":"2011","source":"Hepatobiliary & pancreatic diseases international : HBPD INT","url":"https://pubmed.ncbi.nlm.nih.gov/21269942","citation_count":18,"is_preprint":false},{"pmid":"32848609","id":"PMC_32848609","title":"HIF-1α Mediates TRAIL-Induced Neuronal Apoptosis via Regulating DcR1 Expression Following Traumatic Brain Injury.","date":"2020","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32848609","citation_count":18,"is_preprint":false},{"pmid":"25808868","id":"PMC_25808868","title":"Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25808868","citation_count":16,"is_preprint":false},{"pmid":"10811986","id":"PMC_10811986","title":"Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR).","date":"2000","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10811986","citation_count":16,"is_preprint":false},{"pmid":"27284460","id":"PMC_27284460","title":"TNFRSF10C copy number variation is associated with metastatic colorectal cancer.","date":"2016","source":"Journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27284460","citation_count":15,"is_preprint":false},{"pmid":"15951155","id":"PMC_15951155","title":"Influenza virus-induced glucocorticoid and hypothalamic and lung cytokine mRNA responses in dwarf lit/lit mice.","date":"2005","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15951155","citation_count":15,"is_preprint":false},{"pmid":"8268652","id":"PMC_8268652","title":"The little (lit) mutation cosegregates with the growth hormone releasing factor receptor on mouse chromosome 6.","date":"1993","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/8268652","citation_count":15,"is_preprint":false},{"pmid":"14525947","id":"PMC_14525947","title":"Increases in weight of growth hormone-deficient and immunodeficient (lit/scid) dwarf mice after grafting of hGH-secreting, primary human keratinocytes.","date":"2003","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/14525947","citation_count":15,"is_preprint":false},{"pmid":"24534820","id":"PMC_24534820","title":"Does DcR1 (TNF-related apoptosis-inducing-ligand Receptor 3) have any role in human AMD pathogenesis?","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24534820","citation_count":14,"is_preprint":false},{"pmid":"19414356","id":"PMC_19414356","title":"Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas.","date":"2009","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19414356","citation_count":14,"is_preprint":false},{"pmid":"30225159","id":"PMC_30225159","title":"TNFRSF10C methylation is a new epigenetic biomarker for colorectal cancer.","date":"2018","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/30225159","citation_count":14,"is_preprint":false},{"pmid":"36283772","id":"PMC_36283772","title":"TriD-LAMP: A pump-free microfluidic chip for duplex droplet digital loop-mediated isothermal amplification analysis.","date":"2022","source":"Analytica chimica acta","url":"https://pubmed.ncbi.nlm.nih.gov/36283772","citation_count":14,"is_preprint":false},{"pmid":"3754480","id":"PMC_3754480","title":"Retarded growth of the suprachiasmatic nucleus and pineal body in dw and lit dwarf mice.","date":"1986","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/3754480","citation_count":13,"is_preprint":false},{"pmid":"19936781","id":"PMC_19936781","title":"DcR1 expression in endometrial carcinomas.","date":"2009","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19936781","citation_count":12,"is_preprint":false},{"pmid":"2838765","id":"PMC_2838765","title":"Restoration of microcephalic cerebrum with hypomyelination in the growth hormone-deficient mouse (lit): stimulatory effects of GH restricted to the first 20 days of postnatal life.","date":"1988","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/2838765","citation_count":12,"is_preprint":false},{"pmid":"4007110","id":"PMC_4007110","title":"Abnormal neuronal growth in the little (lit) cerebrum.","date":"1985","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/4007110","citation_count":12,"is_preprint":false},{"pmid":"28968978","id":"PMC_28968978","title":"Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28968978","citation_count":11,"is_preprint":false},{"pmid":"22144989","id":"PMC_22144989","title":"TRAIL and DcR1 expressions are differentially regulated in the pancreatic islets of STZ- versus CY-applied NOD mice.","date":"2011","source":"Experimental diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/22144989","citation_count":11,"is_preprint":false},{"pmid":"11848467","id":"PMC_11848467","title":"Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer.","date":"2001","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11848467","citation_count":11,"is_preprint":false},{"pmid":"34081058","id":"PMC_34081058","title":"Effects of Including Sprints in LIT Sessions during a 14-d Camp on Muscle Biology and Performance Measures in Elite Cyclists.","date":"2021","source":"Medicine and science in sports and exercise","url":"https://pubmed.ncbi.nlm.nih.gov/34081058","citation_count":11,"is_preprint":false},{"pmid":"31940171","id":"PMC_31940171","title":"Ion Mobility Separation Using a Dual-LIT Miniature Mass Spectrometer.","date":"2020","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31940171","citation_count":10,"is_preprint":false},{"pmid":"28043144","id":"PMC_28043144","title":"Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer.","date":"2017","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/28043144","citation_count":10,"is_preprint":false},{"pmid":"34072861","id":"PMC_34072861","title":"Lampenflora in a Show Cave in the Great Basin Is Distinct from Communities on Naturally Lit Rock Surfaces in Nearby Wild Caves.","date":"2021","source":"Microorganisms","url":"https://pubmed.ncbi.nlm.nih.gov/34072861","citation_count":10,"is_preprint":false},{"pmid":"7510770","id":"PMC_7510770","title":"Regulation of metabolic water and protein compartments by insulin-like growth factor-I and testosterone in growth hormone-deficient lit/lit mice.","date":"1993","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7510770","citation_count":10,"is_preprint":false},{"pmid":"25529694","id":"PMC_25529694","title":"Quantitative assessment of moniliformin in cereals via alternative precipitation pathways, aided by LC-LIT-MS and LC-Q-TOF-MS.","date":"2014","source":"Food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25529694","citation_count":9,"is_preprint":false},{"pmid":"18786976","id":"PMC_18786976","title":"MPI-LIT: a literature-curated dataset of microbial binary protein--protein interactions.","date":"2008","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18786976","citation_count":9,"is_preprint":false},{"pmid":"34346473","id":"PMC_34346473","title":"Rational design and development of a lit-active photoswitchable inhibitor targeting CENP-E.","date":"2021","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34346473","citation_count":9,"is_preprint":false},{"pmid":"36334369","id":"PMC_36334369","title":"Lit-LAMP-DNA-vaccine for shrimp allergy prevents anaphylactic symptoms in a murine model.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36334369","citation_count":9,"is_preprint":false},{"pmid":"23584885","id":"PMC_23584885","title":"Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.","date":"2013","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/23584885","citation_count":9,"is_preprint":false},{"pmid":"30044014","id":"PMC_30044014","title":"ATP boosts lit state formation and activity of Arabidopsis cryptochrome 2.","date":"2018","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30044014","citation_count":8,"is_preprint":false},{"pmid":"15165994","id":"PMC_15165994","title":"Regulation of full-length and truncated growth hormone (GH) receptor by GH in tissues of lit/lit or bovine GH transgenic mice.","date":"2004","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15165994","citation_count":8,"is_preprint":false},{"pmid":"35226068","id":"PMC_35226068","title":"Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL.","date":"2023","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35226068","citation_count":7,"is_preprint":false},{"pmid":"37899021","id":"PMC_37899021","title":"Part-night exposure to artificial light at night has more detrimental effects on aphid colonies than fully lit nights.","date":"2023","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37899021","citation_count":7,"is_preprint":false},{"pmid":"17269740","id":"PMC_17269740","title":"Dual-source mass spectrometer with MALDI-LIT-ESI configuration.","date":"2007","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/17269740","citation_count":7,"is_preprint":false},{"pmid":"12417331","id":"PMC_12417331","title":"Transcription initiation sites and promoter structure of the human TRAIL-R3 gene.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12417331","citation_count":7,"is_preprint":false},{"pmid":"24428732","id":"PMC_24428732","title":"Lost in Translation (LiT): IUPHAR Review 6.","date":"2014","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24428732","citation_count":6,"is_preprint":false},{"pmid":"38528786","id":"PMC_38528786","title":"Genistein Enhances TRAIL-Mediated Apoptosis Through the Inhibition of XIAP and DcR1 in Colon Carcinoma Cells Treated with 5-Fluorouracil.","date":"2024","source":"Turkish journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38528786","citation_count":6,"is_preprint":false},{"pmid":"15110171","id":"PMC_15110171","title":"Transcriptional regulation of the TRAIL-R3 gene.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110171","citation_count":6,"is_preprint":false},{"pmid":"25548171","id":"PMC_25548171","title":"β-Catenin-related protein WRM-1 is a multifunctional regulatory subunit of the LIT-1 MAPK complex.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25548171","citation_count":6,"is_preprint":false},{"pmid":"37587751","id":"PMC_37587751","title":"Color-Tuning Mechanism of the Lit Form of Orange Carotenoid Protein.","date":"2023","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/37587751","citation_count":6,"is_preprint":false},{"pmid":"33033848","id":"PMC_33033848","title":"Liver infusion tryptose (LIT): the best choice for growth, viability, and infectivity of Leishmania infantum parasites.","date":"2020","source":"Parasitology research","url":"https://pubmed.ncbi.nlm.nih.gov/33033848","citation_count":6,"is_preprint":false},{"pmid":"2980124","id":"PMC_2980124","title":"Growth hormone and prolactin immunoreactivity in the pituitary gland of postnatal little (lit) mice.","date":"1986","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/2980124","citation_count":6,"is_preprint":false},{"pmid":"1504465","id":"PMC_1504465","title":"Histopathology of the pituitary gland in neonatal little (lit) mutant mice.","date":"1992","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/1504465","citation_count":6,"is_preprint":false},{"pmid":"15644570","id":"PMC_15644570","title":"Diurnal variation in growth hormone receptor messenger ribonucleic acid in liver and skeletal muscle of lit/+ and lit/lit mice.","date":"2004","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/15644570","citation_count":6,"is_preprint":false},{"pmid":"40097274","id":"PMC_40097274","title":"Lit-OTAR framework for extracting biological evidences from literature.","date":"2025","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/40097274","citation_count":6,"is_preprint":false},{"pmid":"31399243","id":"PMC_31399243","title":"Hypermethylation of DcR1, DcR2, DR4, DR5 gene promoters and clinical significance in tongue carcinoma.","date":"2019","source":"American journal of otolaryngology","url":"https://pubmed.ncbi.nlm.nih.gov/31399243","citation_count":5,"is_preprint":false},{"pmid":"12831538","id":"PMC_12831538","title":"Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.","date":"2003","source":"Hybridoma and hybridomics","url":"https://pubmed.ncbi.nlm.nih.gov/12831538","citation_count":5,"is_preprint":false},{"pmid":"27163863","id":"PMC_27163863","title":"tRid, an enabling method to isolate previously inaccessible small RNA fractions.","date":"2016","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/27163863","citation_count":4,"is_preprint":false},{"pmid":"34017330","id":"PMC_34017330","title":"The Effects of LIT and MLR-Bf on Immune Biomarkers and Pregnancy Outcomes in Women With Previous Early Recurrent Miscarriage: A Retrospective Study.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34017330","citation_count":4,"is_preprint":false},{"pmid":"37866191","id":"PMC_37866191","title":"Pro-social and pro-cognitive effects of LIT-001, a novel oxytocin receptor agonist in a neurodevelopmental model of schizophrenia.","date":"2023","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37866191","citation_count":4,"is_preprint":false},{"pmid":"39842051","id":"PMC_39842051","title":"Impact of lymphocyte immunotherapy (LIT) on fertility rates in recurrent pregnancy loss (RPL) women with antinuclear antibodies: A randomized clinical trial.","date":"2025","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39842051","citation_count":4,"is_preprint":false},{"pmid":"38296176","id":"PMC_38296176","title":"Anti-Shigella and antioxidant-based screening of some Cameroonian medicinal plants, UHPLC-LIT-MS/MS fingerprints, and prediction of pharmacokinetic and drug-likeness properties of identified chemicals.","date":"2024","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38296176","citation_count":3,"is_preprint":false},{"pmid":"37343127","id":"PMC_37343127","title":"All Lit Up: Exploring the Photophysical Properties of Protein Polymers.","date":"2023","source":"The journal of physical chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/37343127","citation_count":2,"is_preprint":false},{"pmid":"15196039","id":"PMC_15196039","title":"Identification of essential residues within Lit, a cell death peptidase of Escherichia coli K-12.","date":"2004","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15196039","citation_count":2,"is_preprint":false},{"pmid":"35978826","id":"PMC_35978826","title":"Predictive value of Leukocyte ImmunoTest (LIT™) in cancer patients: a prospective cohort study.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35978826","citation_count":2,"is_preprint":false},{"pmid":"17301872","id":"PMC_17301872","title":"Random-dot pattern design of a light guide in an edge-lit backlight: integration of optical design and dot generation scheme by the molecular-dynamics method.","date":"2007","source":"Journal of the Optical Society of America. A, Optics, image science, and vision","url":"https://pubmed.ncbi.nlm.nih.gov/17301872","citation_count":2,"is_preprint":false},{"pmid":"31163142","id":"PMC_31163142","title":"Motor Evolution: Lit-Up Hydra Bare All.","date":"2019","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/31163142","citation_count":1,"is_preprint":false},{"pmid":"29845022","id":"PMC_29845022","title":"Hypermethylation of DcR1 Gene-based Biomarker in Non-invasive Cancer Screening of Vietnamese Cervical Cancer Patients.","date":"2018","source":"Iranian journal of public health","url":"https://pubmed.ncbi.nlm.nih.gov/29845022","citation_count":1,"is_preprint":false},{"pmid":"35412430","id":"PMC_35412430","title":"Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).","date":"2022","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/35412430","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50576,"output_tokens":3219,"usd":0.100006},"stage2":{"model":"claude-opus-4-6","input_tokens":6628,"output_tokens":2651,"usd":0.149122},"total_usd":0.249128,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL-R3 (TNFRSF10C) is a plasma membrane-bound protein that binds TRAIL with high affinity but lacks a cytoplasmic domain and is instead glycosyl-phosphatidylinositol (GPI)-linked; unlike TRAIL-R1 and TRAIL-R2, overexpression of TRAIL-R3 does not induce apoptosis in a transient expression system.\",\n      \"method\": \"Cloning, transient expression, quantitative TRAIL binding studies, structural analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original cloning paper with direct binding assays, structural characterization, and functional overexpression studies; foundational study replicated across multiple subsequent works\",\n      \"pmids\": [\"9314565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TRAIL-R3 (TRID) functions as an antiapoptotic decoy receptor that competes with DR4 and DR5 for TRAIL binding, thereby protecting cells from TRAIL-induced apoptosis; TRID gene expression is induced by genotoxic agents (ionizing radiation, MMS) in a p53-dependent manner, identifying TRID as a p53-regulated DNA damage-inducible gene.\",\n      \"method\": \"Reporter assays, genotoxic agent treatment, exogenous p53 expression in p53-null cells, RT-PCR\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (p53 overexpression, genotoxic stress, RT-PCR) in a single study; replicated by subsequent independent labs\",\n      \"pmids\": [\"10435597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Rel/NF-κB transcription factors upregulate DcR1 (TNFRSF10C) expression, and this upregulation confers TRAIL resistance; the resistance is abolished when DcR1 is removed from the cell surface by phosphatidylinositol phospholipase C treatment, establishing the GPI-anchored DcR1 as a dominant-negative inhibitor of TRAIL-mediated apoptosis at the membrane level.\",\n      \"method\": \"DNA arrays, RT-PCR, immunofluorescence, overexpression of cRel, TNFα stimulation, phosphatidylinositol-PLC treatment to remove cell-surface DcR1, TRAIL apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches including gain-of-function, pharmacological removal of surface receptor, and functional apoptosis rescue; single lab but strong mechanistic rigor\",\n      \"pmids\": [\"11350953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Tumor-specific loss of DcR1 (TNFRSF10C) expression in neuroblastoma and other tumor cell lines is caused by dense CpG island hypermethylation of the DcR1 promoter; treatment with the demethylating agent 5-aza-2'-deoxycytidine partially restores DcR1 mRNA expression.\",\n      \"method\": \"Bisulfite sequencing, methylation analysis, 5-aza-2'-deoxycytidine demethylation treatment, RT-PCR\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — demethylation rescue experiment directly links promoter methylation to silencing; independently replicated across multiple tumor types in multiple subsequent studies\",\n      \"pmids\": [\"11929838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The TRAIL-R3 (TNFRSF10C) gene contains a p53 consensus binding element within its first intron; this element binds p53 and confers responsiveness to genotoxic damage in luciferase reporter assays, establishing a direct transcriptional regulatory mechanism by which p53 induces TRAIL-R3 expression.\",\n      \"method\": \"Promoter cloning, transient transfection luciferase reporter assays, electrophoretic mobility shift assay (p53 binding to intronic element), p53 mutant and E6-expressing cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct p53 binding to a defined intronic element demonstrated with multiple genetic controls (temperature-sensitive p53, E6-mediated p53 degradation, p53-null cells); mechanistic rigor is strong\",\n      \"pmids\": [\"14623878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The minimal promoter of TRAIL-R3 lies within 33 nucleotides upstream of the transcription start site and contains a consensus TATA box; the promoter can be induced in doxorubicin-treated MCF-7 cells also in a p53-independent manner.\",\n      \"method\": \"Promoter cloning, mapping of transcriptional start sites, transient transfection luciferase reporter assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay directly demonstrates promoter activity; single lab with limited mechanistic follow-up on p53-independent induction\",\n      \"pmids\": [\"12417331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In p53 wild-type colon cancer cells, oxaliplatin causes p53-dependent upregulation of DcR1, which then sequesters TRAIL and blunts TRAIL-induced apoptosis; siRNA knockdown of DcR1 restores oxaliplatin/TRAIL synergistic apoptosis, and exogenous DcR1 overexpression in p53-mutant cells abolishes this synergy, demonstrating that DcR1 acts downstream of p53 to inhibit TRAIL signaling.\",\n      \"method\": \"siRNA knockdown of DcR1, exogenous DcR1 overexpression, apoptosis assays across multiple colon cancer cell lines with defined p53 status\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain- and loss-of-function experiments with defined p53 genetic background; multiple cell lines tested\",\n      \"pmids\": [\"18345033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TNFRSF10C is inactivated in prostate cancer through a combination of hemizygous chromosomal deletion and promoter CpG island hypermethylation; demethylation of the promoter with 5-aza-2'-deoxycytidine in PC3 cells restores TNFRSF10C mRNA expression, demonstrating that promoter methylation is a mechanistic cause of gene silencing.\",\n      \"method\": \"Bisulfite sequencing, Affymetrix SNP array for deletion analysis, 5-aza-2'-deoxycytidine treatment, real-time RT-PCR in clinical specimens and cell lines\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — demethylation rescue in cell line plus genomic deletion mapping in clinical specimens; two independent silencing mechanisms characterized\",\n      \"pmids\": [\"19035483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Down-modulation of TRAIL-R3 in AML blasts enhances TRAIL-induced cell death, confirming its functional role as a decoy receptor on leukemic cells; high TRAIL-R3 expression confers resistance to soluble TRAIL-induced apoptosis.\",\n      \"method\": \"Flow cytometry, siRNA-mediated knockdown of TRAIL-R3, TRAIL apoptosis assays in primary AML blasts\",\n      \"journal\": \"Leukemia research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional knockdown with defined apoptosis readout in primary patient material; single lab\",\n      \"pmids\": [\"21269942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DcR1 (TNFRSF10C) is induced by temozolomide in glioma cells through a p50/NF-κB1- and Bcl3-dependent mechanism requiring a conserved κB-site in the proximal DcR1 promoter; DcR1 attenuates temozolomide efficacy by blunting Fas receptor pathway activation, and DcR1 depletion enhances temozolomide efficacy in intracranial xenografts.\",\n      \"method\": \"NF-κB reporter assays, κB-site mutagenesis, loss-of-function (siRNA) and gain-of-function DcR1 studies, intracranial xenograft model, apoptosis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter mutagenesis, reciprocal loss/gain of function, in vivo xenograft validation; multiple orthogonal methods in single study\",\n      \"pmids\": [\"25808868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HIF-1α negatively regulates DcR1 expression following traumatic brain injury; pharmacological inhibition of HIF-1α or HIF-1α siRNA increases DcR1 expression in neurons, which in turn reduces TRAIL/DR5-mediated neuronal apoptosis, placing DcR1 downstream of HIF-1α in the TRAIL apoptotic pathway.\",\n      \"method\": \"HIF-1α inhibitor (2ME) and agonist (DMOG) treatment in rat TBI model, HIF-1α siRNA in vitro, Western blot, immunofluorescence, TRAIL/DR5 blockade with soluble DR5\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo pharmacological and in vitro siRNA approaches converge; single lab with multiple methods\",\n      \"pmids\": [\"32848609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Hepatitis B virus (HBV) upregulates TRAIL-R3 expression in hepatocytes through hepatitis B x (HBx) protein-mediated activation of NF-κB signaling acting on the TRAIL-R3 promoter region (-969 to -479 upstream of transcription start); TRAIL-R3 upregulation inhibits both TRAIL-dependent apoptosis and TRAIL-mediated suppression of HBV replication, providing a mechanism for HBV immune escape.\",\n      \"method\": \"cDNA microarray and NGS in HBV-infected humanized mouse livers, in vitro HBV replication models, luciferase promoter assays, antiviral nucleotide treatment, in vivo and in vitro validation\",\n      \"journal\": \"The Journal of infectious diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter mapping, in vivo and in vitro HBV replication models, antiviral rescue; multiple orthogonal methods with mechanistic resolution\",\n      \"pmids\": [\"35226068\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF10C (DcR1/TRAIL-R3) is a GPI-anchored, cytoplasmic domain-lacking decoy receptor that binds TRAIL with high affinity but fails to transduce apoptotic signals, instead acting as a dominant-negative inhibitor of TRAIL-mediated apoptosis by competing with death receptors DR4 and DR5; its expression is transcriptionally upregulated by p53 (via an intronic p53-binding element) and NF-κB (via a proximal κB-site, requiring Bcl3/p50), and is epigenetically silenced in many tumors through CpG island promoter hypermethylation, while HBV exploits NF-κB/HBx-mediated TRAIL-R3 induction to escape immune surveillance.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFRSF10C (DcR1/TRAIL-R3) is a GPI-anchored decoy receptor that binds TRAIL with high affinity but lacks a cytoplasmic death domain, thereby competing with the death receptors DR4 and DR5 to inhibit TRAIL-mediated apoptosis at the cell surface [PMID:9314565, PMID:11350953]. Its expression is transcriptionally controlled by p53, which binds a consensus element in the first intron to upregulate DcR1 after genotoxic stress, and by NF-κB, which acts through a proximal κB-site in a p50/Bcl3-dependent manner [PMID:14623878, PMID:25808868]. In many cancers DcR1 is epigenetically silenced by CpG island promoter hypermethylation, sometimes in combination with hemizygous deletion, and demethylation restores its expression [PMID:11929838, PMID:19035483]. Hepatitis B virus exploits HBx-mediated NF-κB activation of the DcR1 promoter to upregulate DcR1 in hepatocytes, thereby blunting TRAIL-dependent immune clearance and antiviral suppression of HBV replication [PMID:35226068].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of TRAIL-R3 as a GPI-anchored receptor that binds TRAIL but cannot signal apoptosis resolved how cells could engage TRAIL without dying, establishing the decoy receptor concept for TRAIL biology.\",\n      \"evidence\": \"Cloning, quantitative TRAIL-binding assays, structural analysis, and transient overexpression in cell lines\",\n      \"pmids\": [\"9314565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No endogenous loss-of-function data to confirm physiological decoy role\", \"Mechanism by which GPI anchor prevents signaling not elucidated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that DcR1 is a p53-inducible DNA damage-response gene explained how genotoxic stress could paradoxically protect certain cells from TRAIL-mediated killing.\",\n      \"evidence\": \"RT-PCR and reporter assays after ionizing radiation and MMS in cells with or without functional p53\",\n      \"pmids\": [\"10435597\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct p53 binding site not yet mapped\", \"Physiological relevance of p53-mediated DcR1 induction in vivo not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showing that NF-κB upregulates surface DcR1 and that its enzymatic removal restores TRAIL sensitivity established DcR1 as a dominant-negative TRAIL inhibitor operating at the plasma membrane.\",\n      \"evidence\": \"cRel overexpression, TNFα stimulation, PI-PLC cleavage of GPI-anchored DcR1, and TRAIL apoptosis assays\",\n      \"pmids\": [\"11350953\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific NF-κB binding site in DcR1 promoter not mapped\", \"Contribution of individual NF-κB subunits not determined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that DcR1 promoter CpG island hypermethylation causes tumor-specific silencing revealed an epigenetic mechanism by which cancers lose a TRAIL decoy, with implications for TRAIL-based therapy sensitivity.\",\n      \"evidence\": \"Bisulfite sequencing in neuroblastoma and other tumor lines; 5-aza-2′-deoxycytidine restores expression\",\n      \"pmids\": [\"11929838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether methylation-mediated DcR1 loss sensitizes tumors to endogenous TRAIL in vivo not shown\", \"Mechanism recruiting methyltransferases to DcR1 locus unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping of a p53-binding element in the first intron and delineation of the minimal TATA-box-containing promoter provided the direct cis-regulatory architecture for p53-dependent and p53-independent transcriptional control of DcR1.\",\n      \"evidence\": \"EMSA demonstrating p53 binding to intronic element; luciferase reporter assays with wild-type and mutant p53, E6-expressing cells, and promoter deletions\",\n      \"pmids\": [\"14623878\", \"12417331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin context of p53 binding (ChIP) not shown\", \"Identity of p53-independent transcriptional activators in doxorubicin-treated cells unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Reciprocal knockdown and overexpression of DcR1 across p53-defined colon cancer lines demonstrated that p53-driven DcR1 induction functionally antagonizes oxaliplatin/TRAIL synergy, establishing DcR1 as a druggable resistance node in combination therapy.\",\n      \"evidence\": \"siRNA knockdown and forced expression of DcR1 in colon cancer lines with defined p53 status; apoptosis quantification\",\n      \"pmids\": [\"18345033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DcR1 depletion improves combination therapy in vivo not tested\", \"Stoichiometric relationship between DcR1 and DR4/DR5 on surface not quantified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of concurrent hemizygous deletion and promoter methylation in prostate cancer showed that biallelic inactivation of DcR1 occurs through complementary genetic and epigenetic hits.\",\n      \"evidence\": \"SNP array for copy-number analysis and bisulfite sequencing in clinical prostate cancer specimens; 5-aza-2′-deoxycytidine rescue in PC3 cells\",\n      \"pmids\": [\"19035483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of DcR1 loss for prostate cancer TRAIL sensitivity not tested directly\", \"Whether deletion is selected for or bystander to neighboring loci unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining the proximal κB-site and p50/Bcl3 dependence for temozolomide-induced DcR1 expression, together with in vivo xenograft validation, resolved the specific NF-κB subunit pathway and established DcR1 depletion as a strategy to enhance alkylating-agent therapy in glioma.\",\n      \"evidence\": \"κB-site mutagenesis in reporter, siRNA/overexpression of DcR1, intracranial xenograft survival studies\",\n      \"pmids\": [\"25808868\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ChIP confirmation of endogenous p50/Bcl3 occupancy at κB-site not provided\", \"Whether DcR1 inhibits Fas pathway by direct ligand competition or indirect mechanism not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placing DcR1 downstream of HIF-1α as a negatively regulated target in traumatic brain injury added a hypoxia-responsive layer to DcR1 transcriptional control in neurons.\",\n      \"evidence\": \"HIF-1α inhibitor/agonist treatment in rat TBI model and HIF-1α siRNA in vitro; Western blot and immunofluorescence\",\n      \"pmids\": [\"32848609\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HIF-1α binding to DcR1 promoter not demonstrated\", \"Mechanism of negative regulation (direct repression vs. indirect) unknown\", \"Single-lab finding not yet independently replicated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that HBV/HBx upregulates DcR1 via NF-κB to simultaneously block TRAIL-mediated apoptosis and TRAIL-dependent antiviral suppression revealed a viral immune evasion strategy centered on the decoy receptor.\",\n      \"evidence\": \"cDNA microarray/NGS in HBV-infected humanized mouse livers, luciferase promoter assays mapping -969 to -479 region, in vitro HBV replication models, antiviral rescue\",\n      \"pmids\": [\"35226068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact NF-κB binding element within the -969 to -479 region not fine-mapped\", \"Whether other hepatotropic viruses exploit DcR1 similarly is untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for TRAIL binding by GPI-anchored DcR1, the precise stoichiometry of DcR1/DR4/DR5 competition at the membrane, and whether DcR1 has signaling-independent functions beyond ligand sequestration remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of DcR1–TRAIL complex\", \"Quantitative surface competition model with DR4/DR5 lacking\", \"Potential non-apoptotic signaling through lipid-raft-associated DcR1 unexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 6, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 2, 6, 8, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 4, 9, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFSF10\",\n      \"TP53\",\n      \"NFKB1\",\n      \"BCL3\",\n      \"HBx\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}